Evaluation of MiR-1908-3p as a novel serum biomarker for breast cancer and analysis its oncogenic function and target genes

Table 2 Clinicopathological variables and the expression of miR-1908-3p in the serum of breast cancer

Variable	Number	Mean of miR-1908-3p expression	p value
Age			< 0.001
≤ 40	27 (45%)	30.41
> 40	33 (55%)	5.18
Metastasis			0.723
Negative	25 (42%)	15.42
Positive	35 (58%)	17.33
Grade			0.086
1	11 (18%)	15.77
2	20 (33%)	9.01
3	29 (49%)	22.00
TNM			0.072
I/II	46 (77%)	16.00
III/IV	14 (23%)	18.26
Tumor size			0.721
≤ 2	22 (37%)	15.46
> 2,≤5	35 (58%)	16.42
> 5	3 (5%)	25.73
ER statue			0.65
Negative	19 (32%)	18.29
Positive	41 (68%)	15.72
PR statue			0.418
Negative	22 (37%)	19.36
Positive	38 (63%)	14.89
HER-2			0.489
Negative	52 (87%)	15.81
Positive	8 (13%)	21.22
Molecular Subtype			0.786
luminal	41 (68%)	15.72
her-2+	5 (8%)	14.86
triple-negative	14 (24%)	19.79

Abbreviations: ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2

ISSN: 1471-2407